This model provides a convenient method for researchers to study pulmonary vascular remodeling and advance PAH drug development because it captures important alterations in the pulmonary endothelial phenotype necessary for the induction of SMC remodeling, including a BMPR2-SOX17-prostacyclin. Here, SOX17 is linked to pulmonary arterial hypertension.